Temsirolimus

Temsirolimus

Catalog Number:
M001341703TOK
Mfr. No.:
TOK-T077
Price:
$232
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Temsirolimus is a semisynthetic macrocyclic lactone prepared from Rapamycin. It is a dihydroxymethyl propionic acid ester and analog of Rapamycin. The compound is prepared by selective acylation of the 42-hydroxy group with a protected bis (dihydromethyl) propionic acid, followed by deprotection.
          Temsirolimus is an antiproliferative and antiangiogenic mTOR inhibitor. mTOR protein has a role in integrating environmental signals that affect cell growth and proliferation. It has anti-neoplastic properties and immune-modulating activity. It can be used in kinase phosphatase biology research.
          Temsirolimus is soluble in ethanol, methanol, DMF and DMSO.

          Please contact us at for specific academic pricing.

          Background

          Temsirolimus binds to receptor protein, FKBP12. The complex then binds to mTOR preventing it from interacting with target proteins.

      • Properties
        • CAS Number
          162635-04-3
          Molecular Formula
          C56H87NO16
          Molecular Weight
          1030.3
          Appearance
          White solid
          Other Properties
          Source: semi-synthetic
          Storage
          -20°C

          * For research use only

      • Applications
        • Application Description
          Cancer Applications: Temsirolimus can be used in renal-cell carcinoma (RCC). The rationale for using mTOR inhibitors to treat malignancies has focused on the direct, growth-inhibitory effects.
          It is surprising that Temsirolimus can enhance anti-tumor immunity. In an expimental murine model of RCC (RENCA), the combination of an HSP-based cancer vaccine and Temsirolimus was more effective against tumors than either agent alone. In animal models of tumor vaccines, Temsirolimus enhanced vaccine activity by enhancing effector T-cell function and enhancing production of CD8 memory T cells (Wang et al, 2011).
          Temsirolimus can induce antiproliferative effects by inhibiting mTOR in Bel-7402 liver cancer cells. Viability tests, and flow cytometry was used to analyze cell cycle after treatment. It can inhibit mTOR signaling and proliferation in vitro, for a promising strategy for liver cancer (Li et al, 2013).

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.